**Core Tip:** An outbreak of VIM-producing *Serratia marcescens* occurred in patients admitted to the adult polyvalent intensive care unit of the University of Campania "Luigi Vanvitelli" located in Naples. All the strains revealed the production of VIM. After three decades of carbapenem antibiotics use, the emergence of carbapenem-resistant *Enterobacteriaceae* has become a significant concern and is mandatory a stricter control to preserve its clinical application. This is, to our knowledge, the first outbreak of VIM-producing *Serratia marcescens* occurred in a European hospital.

INTRODUCTION
============

Carbapenem-resistant *Enterobacteriaceae* (CRE) has become a significant public health concern as hospital outbreaks are now being frequently reported and these organisms are becoming difficult to treat with the available antibiotics. Early recognition through molecular characterization, epidemiologic studies, and surveillance is essential to prevent hospital outbreaks of these organisms\[[@B1]\]. *Serratia marcescens* (*S. marcescens*), an aerobic Gram-negative pathogen belonging to the family of *Enterobacteriaceae*, is known to cause hospital-acquired infections, commonly in an outbreak setting. Carbapenem resistance in *S. marcescens* may be chromosomal (SME), or plasmid (KPC, Oxa-48, IMP, NDM and VIM) mediated. Carbapenem resistance in is an ominous event as this pathogen is intrinsically resistant to polymyxins\[[@B2]\]. *S. marcescens* outbreaks in intensive care units (ICUs) are associated with considerable mortality rates, ranging from 14% to 60%\[[@B3],[@B4]\]. Previous *S. marcescens* outbreaks in Italy has been mostly reported in neonatal ICUs (NICUs)\[[@B5]-[@B9]\]. The present study aimed to describe the first Italian nosocomial outbreak of VIM-producing *S. marcescens* occurred in our adult polyvalent ICU located in Campania region, Southern Italy.

CASE PRESENTATION
=================

Chief complaints and history of illness
---------------------------------------

The index case of the outbreak of three patients infected and/or colonized by VIM-producing *S. marcescens* was a 49-year-old man with a history of schizophrenia admitted with a diagnosis of descending necrotizing mediastinitis whose CRE screening at admission was negative.

The second patient was a 69-year-old woman with a history of recurrent episodes of urinary tract infection (UTI) admitted from the community with UTI and septic shock (SS).

The third patient was a 67-year-old woman with various underlying diseases (Paranoid personality disorder, diabetes mellitus, ulcerative colitis, hypothyroidism and hypertrophic cardiomyopathy) who was admitted to our ICU for a hypovolemic haemorrhagic shock.

Examinations
------------

For every patient admitted to our six-bed adult polyvalent ICU, a rectal swab (RS) was obtained (CRE screening) using a Copan Amies sterile transport swab (Copan Diagnostics, Murrieta, CA). The RS was streaked onto Mac Conkey Agar (Biomerieux, Marcy l\'Etoule, France) with a 10 μg meropenem disk. Mac Conkey agar plates were incubated aerobically at 37°C overnight. Antibiotic susceptibility was determined using the disk diffusion method. Suspicious colonies growing into the meropenem disk-halo were picked up and identified using MALDI-TOF MS (Matrix- Assisted Laser Desorption/Ionization Time of Flight mass spectroscopy).

Carbapenem resistance were identified in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines using updated EUCAST breakpoint tables (EUCAST clinical breakpoint valid from 15/05/2018) (Table [1](#T1){ref-type="table"}).

###### 

Antibiotic susceptibilities, in accordance with the European Committee on Antimicrobial Susceptibility Testing of VIM-producing *Serratia marcescens* isolates with the date and first site of identification

         **MIC (μg/mL)**                       
  ------ ----------------- --------- --------- ---------
  AMK    ≤ 4               8         ≤ 4       ≤ 4
  AMC    \> 32/2           \> 32/2   \> 32/2   \> 32/2
  AMP    \> 8              \> 8      \> 8      \> 8
  FEP    \> 8              \> 8      \> 8      \> 8
  CTX    \> 4              \> 4      \> 4      \> 4
  CAZ    \> 8              \> 8      \> 8      \> 8
  CIP    1                 \> 1      0.5       0.5
  CST    \> 4              \> 4      ≤ 1       ≤ 1
  ETP    \> 1              \> 1      \> 1      \> 1
  FOF    ≤ 32              64        ≤ 32      ≤ 32
  GEN    \> 4              \> 4      4         4
  IPM    \> 8              \> 8      \> 8      \> 8
  LVX    2                 \> 2      1         ≤ 0.5
  MEM    \> 8              \> 8      \> 8      8
  PIP    \> 16             \> 16     \> 16     \> 16
  TZP    \> 16/4           \> 16/4   \> 16/4   \> 16/4
  TGC    \> 2              \> 2      \> 2      \> 2
  TOB    \> 4              \> 4      \> 4      \> 4
  SXT    \> 4/76           \> 4/76   \> 4/76   \> 4/76
  Date   Aug, 1            Aug, 17   Sep, 20   Sep, 24
  Site   Blood             Blood     RS        RT

AMC: Amoxicillin-clavulanic acid; AMK: Amikacin; AMP: Ampicillin; CAZ: Ceftazidime; CIP: Ciprofloxacin; CST: Colistin; CTX: Cefotaxime; ETP: Ertapenem; FEP: Cefepime; FOF: Fosfomycin; GEN: Gentamicin; IPM: Imipenem; LVX: Levofloxacin; MEM: Meropenem; PIP: Piperacillin; RS: Rectal swab; RT: Respiratory tract; SXT: Trimethoprim-sulfamethoxazole; TGC: Tigecycline; TOB: Tobramycin; TZP: Piperacillin-tazobactam.

Molecular analysis to identify carbapenemase genes was performed using the Xpert Carba-R Cartridge (GeneXpert^®^, Cepheid, Sunnyvale, CA).

The Xpert Carba-R Assay, conducted on the GeneXpert^®^ device, is an automated qualitative real-time polymerase chain reaction based test that detects specific gene associated with carbapenem resistance(blaKPC , blaNDM, blaVIM, blaOXA-48 and blaIMP-1).

FINAL DIAGNOSIS
===============

After 65 d of the first patient hospitalization, a blood culture grew VIM-producing *S. marcescens*. Three days after the diagnosis of bacteraemia his RS was positive for the same organism. The same patient developed a new episode of bacteraemia during further ICU stay.

The second patient, eleven days after admission in ICU, developed lower respiratory tract infection (LRTI) with bronchial culture positive for VIM-producing *S. marcescens*. Her RS also tested positive for *S. marcescens* on the same day.

VIM-producing *S. marcescens* was isolated in the third patient from tracheal aspirate after seven days and from urine after eleven days of hospitalization. In both cases, the isolated was considered as a contaminant. During the ICU admission she developed an acute respiratory distress syndrome due to *Enterococcus faecium*.

TREATMENT
=========

The first episode of VIM-producing *S. marcescens* bacteraemia was treated with ceftazidime-avibactam (CZA) plus gentamicin for 14-d. The second episode was initially treated with amikacin (AMK) and Fosfomycin. Fosfomycin was later substituted with meropenem due to hypernatremia. The total duration of the antibiotic treatment in this episode was 47 d.

The second patient was treated by the ward of origin with piperacillin-tazobactam (TZP) in association with AMK; initially (September, 12) we treated the SS with ceftolozane-tazobactam (C/T) and metronidazole; ceftaroline, not active against VIM-producing *S. marcescens*, was added later (September, 24), as her condition deteriorated, for a suspected methicillin-resistant *Staphylococcus aureus* infection\[[@B10]\]. The duration of total antibiotic therapy was 14 d.

The third patient was initially empirically treated with tigecycline and TZP; subsequently, due to the worsening of clinical conditions, antibiotic therapy was modified with the introduction of CZA, AMK, Colistin and ampicillin-sulbactam. VIM-producing *S. marcescens*, considered as a contaminant, in the third patient was not treated.

OUTCOME AND FOLLOW-UP
=====================

Both episodes of bacteraemia of the first patient resulted in a favourable outcome: The patient was transferred to a rehabilitation unit at the end of the ICU stay.

The second and the third patient died. Unfortunately for the third patient the microbiological result, with the isolation of the *Enterococcus faecium*, arrived posthumously.

The main clinical and epidemiological characteristics of the patients are reported in Table [2](#T2){ref-type="table"}.

###### 

Clinical and epidemiological data of patients

  **Patient**   **Admission from**            **Age** **(yr)**           **Sex**                         **Underlying** **disease(s)**   **Previous AT**                     **Admission diagnosis**   **Date of admission**         **Stool screening**       **1° site of identifi-cation**
  ------------- ----------------------------- -------------------------- ------------------------------- ------------------------------- ----------------------------------- ------------------------- ----------------------------- ------------------------- --------------------------------
  1             Community                     49                         M                               SC                              No                                  DNM                       May, 28                       Yes                       Blood
  1             ICU                           49                         M                               SC                              Yes                                 DNM                       May, 28                       Yes                       Blood
  2             Community                     69                         F                               rUTI                            Yes                                 SS                        Sep, 9                        Yes                       RS
  3             Internal ward                 67                         F                               PPD, DM, UC, SHT, HCM           Yes                                 HS                        Sep, 17                       Yes                       RT
  **Patient**   **Infection** **(1° site)**   **Date of 1° isolation**   **2° site of identification**   **Infection** **(2° site)**     **Date of the 2° isolation site**   **Initial AT**            **Final AT**                  **AT duration** **(d)**   **Outcome**
  1             Yes                           Aug, 1                     RS                              No                              Aug, 4                              CZA + GEN                 CZA + GEN                     14                        Favourable
  1             Yes                           Aug, 17                    \-                              \-                              \-                                  AMK + FOF                 AMK + MEM                     47                        Favourable
  2             No                            Sep, 20                    RT                              Yes                             Sep, 20                             C/T + MTZ                 C/T + MTZ + CPT               14                        Death
  3             No                            Sep, 24                    Urine                           No                              Sep, 28                             AFG + TGC + TZP           CST + SAM + CZA + AMK + AFG   16                        Death

AFG: Anidulafungin; AMK: Amikacin; AT: Antibiotic treatment; CPT: Ceftaroline; CST: Colistin; C/T: Ceftolozane-tazobactam; CZA: Ceftazidime-avibactam; DM: Diabetes mellitus; DNM: Descending necrotizing mediastinitis; FOF: Fosfomycin; GEN: Gentamicin; HCM: Hypertrophic cardiomyopathy; HS: Hypovolemic hemorrhagic shock; ICU: Intensive care unit; MEM: Meropenem; MTZ: Metronidazole; PPD: Paranoid personality disorder; RS: Rectal swab; RT: Respiratory tract; SAM: Ampicillin-sulbactam; SC: Schizophrenia; SHT: Hypothyroidism; SS: Septic shock; TGC: Tigecycline; TZP: Piperacillin-tazobactam; UC: Ulcerative Colitis; rUTI: Recurrent urinary tract infection.

DISCUSSION
==========

*S. marcescens* is an essential cause of hospital-acquired infections. Although most infections have been linked to hospital outbreaks, occasional infections can occur outside the outbreak settings also. The first hospital outbreak was reported in San Francisco in 1950 where 11 patients developed UTI by *S. marcescens*, one of them complicated by endocarditis\[[@B11]\]. Many hospital outbreaks have been reported after that\[[@B12]\]. It has been associated with various infections including UTI, bloodstream infection, pneumonia, skin and soft tissue infections, meningitis and ocular infections.

Antibiotic resistance has been a worrisome issue to physicians treating infections caused by *S. marcescens*. This organism is intrinsically resistant to a large number of antibiotics including ampicillin, amoxicillin, amoxicillin-clavulanate, ampicillin-sulbactam, narrow-spectrum cephalosporins, cefuroxime, nitrofurantoin, macrolides and polymixins\[[@B13]\]. It also carries a chromosomal AmpC beta-lactamase which when overexpressed can render all beta-lactams except carbapenems ineffective\[[@B14]\]. They also can produce plasmid-mediated extended spectrum beta-lactamase (ESBL) and carbapenemases. Carbapenemases in *S. marcescens* can be chromosomal (SME) or plasmid-mediated (KPC, OXA-48, IMP, VIM, and NDM). Quinolone resistance can arise due to alterations in gyrA, outer membrane proteins, and expression of efflux pumps\[[@B12]\].

Carbapenem resistance can be devastating in case of Serratia infections considering its intrinsic resistance to polymixins. Many outbreaks of KPC2 producing *Serratia marcescens* has been reported\[[@B15],[@B16]\]. Plasmid-mediated Metallo-β-lactamases (IMP, VIM, and NDM-1) which inactivate carbapenems can be produced by some Serratia strains\[[@B17]\].

Nosocomial outbreaks of VIM-producing *S. marcescens* has been reported infrequently in literature, most of them are from NICUs\[[@B18],[@B19]\]. Nosocomial outbreaks of VIM-producing pathogens have been reported in multiple major Gram-negative bacteria, making VIM-producing bacteria a severe public health concern. The first VIM-producing Gram-negative pathogen and the most frequently reported in the literature is *Pseudomonas aeruginosa*, followed by *Klebsiella pneumonia* and *Acinetobacter baumannii* (Table [3](#T3){ref-type="table"}). In our study, VIM-producing *S. marcescens* was isolated in a University Hospital ICU. This is in line with previous reports in the literature because most cases of VIM-producing Gram-negative pathogens have been isolated in ICUs of tertiary care teaching hospitals (Table [3](#T3){ref-type="table"}). Unlike what has been reported in the last ten years in our Country, where the *S. marcescens* outbreaks have mostly taken place in NICUs (Table [4](#T4){ref-type="table"}) this first Italian outbreak of VIM-producing *Serratia marcescens* occurred in an adult ICU. Fatality rate in our outbreak was 50% (2 of 4 episodes), similar to the first nosocomial outbreak of VIM-producing *S. marcescens* happened in Argentina, which however occurred in NICU setting\[[@B19]\]. The high mortality is probably due to the inappropriate use of antibiotics for the treatment of severe infections in ICU patients\[[@B20]\]. In Figure [1](#F1){ref-type="fig"} are represented the mechanisms of action of antibiotics used in our patients with VIM-producing *S. marcescens* infection. Given that no effective treatment is known, isolated reports describe successful therapy combining CZA and Aztreonam. The rationale of this antibiotic association is that Aztreonam remains intact in the presence of carbapenemases but hydrolyzed by ESBLs and CZA neutralizes the ESBLs and AmpC beta-lactamases\[[@B21]\]. In our study CZA was never co-administered with aztreonam, though there was clinical success in one of two patients who were given CZA in combination with other antibiotics (Table [2](#T2){ref-type="table"}).

![Mechanism of antibiotics used in our patients with VIM-producing *Serratia marcescens*. DNA: Deoxyribonucleic acid; PBPs: Penicillin-binding proteins; UDP-MurA: Uridine diphosphate-N-acetylglucosamine enolpyruvyl transferase.](WJCC-7-3535-g001){#F1}

###### 

Previous reported hospital outbreaks around the world of VIM-producing Gram-negative pathogens

  **Year**   **City, Country, time span**                                                **Pathogen**                **Type of Hospital**                                 **Setting**                                   **VIM cases**   **Comments**
  ---------- --------------------------------------------------------------------------- --------------------------- ---------------------------------------------------- --------------------------------------------- --------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  2000       Verona, Italy; February 1997 - February 1998\[[@B29]\]                      *Pseudomonas aeruginosa*    University Hospital                                  ICU patients                                  83              All patients from ICU
  2000       Thessaloniki, Greece; 1996-1998\[[@B30]\]                                   *Pseudomonas aeruginosa*    University Hospital                                  ICU patients                                  211             More than one sample for patient;
  2001       Southern Taiwan; January 1999 - December 2000\[[@B31]\]                     *Klebsiella pneumoniae*     University Medical Center                            ICU and Other Wards                           5               Multidrug-resistant *Klebsiella pneumoniae*
  2004       Heraklion, Greece; Summer 2001\[[@B32]\]                                    *Escherichia coli*          University Hospital                                  ICU patients                                  4               All patients from ICU
  2004       Cali, Colombia; February 1999 - July 2003\[[@B33]\]                         *Pseudomonas aeruginosa*    Tertiary Care Medical Center                         ICU patients                                  66              All patients from ICU
  2005       Larissa and Thessaloniki, Greece; December 2004 - March 2005\[[@B34]\]      *Klebsiella pneumoniae*     University Hospital                                  ICU and Other Wards                           27              Outbreaks in distinct regions due to a single *Klebsiella pneumoniae* clone
  2005       Calgary, Canada; May 2002 - April 2004\[[@B35]\]                            *Pseudomonas aeruginosa*    1 pediatric and 3 large adult hospitals              ICU and Other Wards                           228             Population-based epidemiological study of infections
  2005       USA; May 2013\[[@B36]\]                                                     *Pseudomonas aeruginosa*    Public Teaching Hospital                             ICU and Other Wards                           17              First outbreak of carbapenemase in USA
  2005       Porto Alegre, southern Brazil; January - October 2004\[[@B37]\]             *Pseudomonas aeruginosa*    Tertiary-care Teaching Hospital                      ICU and Other Wards                           135             Outbreak of carbapenem-resistant
  2006       Athens, Greece; March 2002-October 2002\[[@B38]\]                           *Acinetobacter baumannii*   Tertiary Care Hospital                               ICU and Other Wards                           15              Outbreak of multiple clones of imipenem-resistant
  2006       Paris, France; 2003-2004\[[@B39]\]                                          *Klebsiella pneumoniae*     Teaching Hospital                                    ICU and Other Wards                           8               Recovered from clinical specimens or rectal swabs - Surgical ward or ICU patients
  2006       Trieste, Italy; 1996-1997/ 2000-2002\[[@B40]\]                              *Pseudomonas aeruginosa*    University Hospital                                  ICU and Other Wards                           91              Nosocomial setting of high-level endemicity
  2006       Hungary; October 2003-November 2005\[[@B41]\]                               *Pseudomonas aeruginosa*    seven hospitals in Hungary                           ICU and Other Wards                           19              Molecular epidemiology of VIM-4 *Pseudomonas sp*
  2007       Madrid, Spain; March 2005 - September 2006\[[@B42]\]                        *Enterobacteriaceae*        University Hospital                                  ICU and Other Wards                           25              (52% of patients were in ICU)
  2007       Warsaw, Poland ; September 2003 - May2004/July 2005-January2006\[[@B43]\]   *Pseudomonas aeruginosa*    Tertiary Care Hospital                               ICU and Other Wards                           41              Outbreak of *Pseudomonas aeruginosa* infections
  2007       Athens, Greece; 14 September -3 October 2005\[[@B44]\]                      *Pseudomonas aeruginosa*    University Hospital                                  ICU and Other Wards                           5               Ventilator-Associated Pneumonia (VAP)
  2008       Serres, Greece; April 2005 - March 2007\[[@B45]\]                           *Acinetobacter baumanni*    General Hospital                                     ICU patients                                  31              All patients from ICU
  2008       Piraeus, Greece; 2005-2006\[[@B46]\]                                        *Acinetobacter baumannii*   General Hospital                                     ICU and Other Wards                           6               4 ICU patients
  2008       Genoa, Italy; September 2004 - March 2005\[[@B47]\]                         *Klebsiella pneumoniae*     Tertiary Care Hospital                               ICU and Other Wards                           9               Bloodstream infections
  2008       Athens, Greece; February 2004 - March 2006\[[@B48]\]                        *Klebsiella pneumoniae*     three hospitals in Athens                            ICU and Other Wards                           67              77% ICU patients
  2008       Thessaloniki, Greece; November 2006 - April 2007\[[@B49]\]                  *Klebsiella pneumoniae*     Tertiary Care Hospital                               Wards                                         9               Patients hospitalized in different medical and surgical wards
  2008       Nantes, France; April 1996 - July 2004\[[@B50]\]                            *Pseudomonas aeruginosa*    University Hospital                                  ICU and Other Wards                           59              Mostly urinary tract infections and pneumonia
  2008       UK; November 2003-November 2007\[[@B51]\]                                   *Pseudomonas aeruginosa*    12 UK Hospital                                       ICU patients                                  32              15 cases from same hospital
  2009       Greece; February 2008 - December 2008\[[@B52]\]                             *Klebsiella pneumoniae*     21 Greek hospitals                                   ICU patients                                  52              All patients from ICU
  2009       Thessaloniki, Greece; November 2004 - December 2005\[[@B53]\]               *Pseudomonas aeruginosa*    University Hospital                                  ICU patients                                  29              All patients from ICU
  2010       Zonguldak, Turkey; 2003--2006\[[@B54]\]                                     *Acinetobacter baumannii*   University Hospital                                  ICU and Other Wards                           116             Tracheal aspirates (32%), wound swabs (22%), blood (14%), bronchoalveolar specimens (11%) and urine, sterile fluids, catheter tips, abscess and sputum (each \< 5%).
  2010       Texas, USA; February-June 2008/March-June2009\[[@B55]\]                     *Enterobacter cloacae*      Children's Hospital                                  Children ICU and Other Wards                  3               Fecal colonization
  2010       France; 2003-2004\[[@B56]\]                                                 *Klebsiella pneumoniae*     care centre for abdominal surgery                    ICU and Other Wards                           8               Rectal swab, urine culture, blood culture, tracheal aspirates
  2010       Athens, Greece; February - December 2009\[[@B57]\]                          *Klebsiella pneumoniae*     University Hospital                                  ICU and Other Wards                           42              Hospital-acquired infections
  2010       Wuerzburg, Germany; November - December 2007\[[@B58]\]                      *Pseudomonas aeruginosa*    retrograde urography associated infection            ICU and Other Wards                           11              Strains from urine or urological infection
  2010       Kobe, Japan; September 2007-July 2008\[[@B59]\]                             *Pseudomonas aeruginosa*    Medical Center General Hospital                      ICU patients                                  35              All patients from ICU
  2011       Athens, Greece; March 2004 - November 2005\[[@B60]\]                        *Enterobacteriaceae*        University Hospital                                  ICU patients                                  23              All patients from ICU
  2011       Kasserine Tunisia; 2009 - June 2010\[[@B61]\]                               *Escherichia coli*          University Hospital                                  ICU patients                                  2               Rectal swab
  2011       Essen, Germany; July 2010 - January 2011\[[@B62]\]                          *Klebsiella pneumoniae*     University Hospital                                  ICU and Other Wards                           7               Perianal or rectal swabs
  2011       Tunis, Tunisia; January - November 2008\[[@B63]\]                           *Pseudomonas aeruginosa*    University Hospital                                  ICU and Other Wards                           16              All patients of the kidney transplantation unit; 20 strains from urine, 3 from cutaneous pus, and 1 from blood
  2011       Murcia, Spain; 11-25 May 2009\[[@B64]\]                                     *Pseudomonas aeruginosa*    Tertiary Care Hospital                               ICU and Other Wards                           6               4 ICU patients; strains from blood and sputum
  2011       Central Japan; January 2006 - June 2009\[[@B65]\]                           *Pseudomonas aeruginosa*    University Hospital                                  ICU and Other Wards                           51              Mainly detected by urine culture in the first half, whereas isolation from respiratory tract samples became dominant in the latter half of the outbreak
  2011       Rooterdam, Netherlands; January 2008 - November 2009\[[@B66]\]              *Pseudomonas aeruginosa*    University Hospital                                  ICU and Other Wards                           35              161 carbapenemase-producing: 74 (70%) were isolated from respiratory tract specimens, 6 (6%) from urine, 5 (5%) from blood, 8 (8%) from soft tissue or bone, 7 (7%) from intra-abdominal specimens and 6 (6%) from various other specimens.
  2012       Chosun, Korea; January 2004 - December 200\[[@B67]\]                        *Acinetobacter baumannii*   University Hospital                                  ICU patients                                  77              All patients from ICU
  2012       Madrid, Spain; January 2009 - December 2009\[[@B68]\]                       *Klebsiella pneumoniae*     University Hospital                                  ICU patients                                  28              Fatality rate was 13/28 (46%)
  2012       UK; 2005 -- 2011\[[@B69]\]                                                  *Pseudomonas aeruginosa*    Tertiary Care and University Hospitals               ICU and Other Wards                           89              Fatality rate was 34/89 (38.2%)
  2012       Cape Town, South Africa; January 2010 - April 2011\[[@B70]\]                *Pseudomonas aeruginosa*    Tertiary Care and University Hospitals               ICU patients                                  15              10 strains from blood, 2 from stool, 1 from bile, 1 from urine and 1 from a catheter tip
  2013       Bologna, Italy; 1-15 June 2012\[[@B71]\]                                    *Citrobacter freundii*      University Hospital                                  ICU patients                                  8               Rectal swab
  2013       Abidjan, Ivory Coast; February 2009 - November 2011\[[@B72]\]               *Pseudomonas aeruginosa*    University Hospital                                  ICU patients                                  12              All patients from ICU
  2013       Thessalia, Larissa, Greece; 2010-2012\[[@B73]\]                             *Pseudomonas aeruginosa*    University Hospital                                  ICU and Other Wards                           49              All patients from ICU
  2013       Taiwan; 2003-2007\[[@B74]\]                                                 *Pseudomonas aeruginosa*    Regional Hospital                                    ICU and Other Wards                           50              8 ICU patients
  2013       Buenos Aires, Argentina; July--September 2011\[[@B19]\]                     *Serratia marcescens*       Tertiary Care Neonatal University Hospital           Neonatal ward patients                        3               Rectal swab; fatality rate was 1/2 (50%) and one lost at follow-up
  2014       Split, Croatia; June - August 2012\[[@B75]\]                                *Enterobacter cloacae*      University Hospital                                  ICU patients                                  6               Strains from lower respiratory tract, blood, abdominal cavity and rectum; fatality rate was 4/6 (66.6%)
  2014       Greece; 2003-2007\[[@B76]\]                                                 *Klebsiella pneumoniae*     Tertiary Care and University Hospitals               ICU patients                                  21              All patients from ICU
  2014       Rome, Italy; 2011-2012\[[@B77]\]                                            *Pseudomonas aeruginosa*    Tertiary Care Paediatric Hospital                    Children with onco-haematological diseases;   27              12 cases of bacteraemia, 6 other infections and 9 colonized; mortality rate was 67%
  2014       Leiden, Netherlands; 2004- January 2012\[[@B78]\]                           *Pseudomonas aeruginosa*    University Hospital                                  ICU patients                                  20              All patients from ICU
  2014       China; December 2006 - July 2008\[[@B79]\]                                  *Pseudomonas aeruginosa*    Tertiary Care Hospitals                              ICU patients                                  1               All patients from ICU
  2015       Madrid, Spain - January 2009 - February 2014\[[@B80]\]                      *Klebsiella pneumoniae*     University Hospital                                  ICU and Other Wards                           37              OXA-48 ST11 clone
  2015       Athens, Greece; September--November 2011\[[@B81]\]                          *Providencia stuartii*      Tertiary Care Hospital                               ICU patients                                  10/5            Strains from blood/urine; fatality rate was 7/15 (46.6%)
  2015       Rotterdam, Netherlands; January - April 2012\[[@B82]\]                      *Pseudomonas aeruginosa*    University Hospital                                  ICU and Other Wards                           30              9 ICU patients; patients undergone ERCP using a specific duodenoscope (TJF-Q180V)
  2015       UK, 2003 -- 2012\[[@B83]\]                                                  *Pseudomonas aeruginosa*    89 Tertiary Care Hospitals                           ICU and Other Wards                           267             Strains from urine (24%), respiratory (18%), wounds (17%) and blood (13%)
  2016       Patras, Greece, January 2005 December 2014\[[@B84]\]                        *Klebsiella pneumoniae*     University Hospital                                  ICU and Other Wards                           45              1668 carbapenemase-producing isolates
  2016       Athens, Greece; December 2012 - March 2013\[[@B85]\]                        *Providencia stuartii*      Tertiary Care Hospital                               ICU patients                                  6               Fatality rate was 3/6 (50%)
  2016       China; August 2011-July 2012\[[@B86]\]                                      *Pseudomonas aeruginosa*    27 Tertiary Care Hospitals                           ICU and Other Wards                           49/44/42        Strains from pus/blood/urine
  2017       Norway; 2007-2014\[[@B87]\]                                                 *Enterobacteriacee*         University Hospital                                  ICU and Other Wards                           14              *Klebsiella pneumoniae* (*n* = 10) and *E. coli* (*n* = 4)
  2017       Jalisco, Mexico; September 2014 - July 2015\[[@B88]\]                       *Enterobacteriacee*         Hospital Civil                                       ICU and Other Wards                           3               *Klebsiella pneumoniae* (*n*=2), *C. freundii* (*n* = 1)
  2017       Madrid, Spain - February 2014\[[@B89]\]                                     *Klebsiella oxytoca*        Children hospital                                    NICU                                          8               8 VIM-Kox/4 also had VIM-Serratia/3 patients VIM -Enterobacteriaceae. NICU, In neonates with any symptom of infection, urine, blood, broncho-alveolar lavages and other samples based on the most likely focus of infection
  2017       UK; 2005-2011\[[@B90]\]                                                     *Pseudomonas aeruginosa*    Two University Hospitals in London and South Coast   ICU and Other Wards                           85              31 ICU patients; fatality rate was 34/85 (40%)
  2018       Thessaloniki, Greece; January 2013- January 2015\[[@B91]\]                  *Klebsiella pneumoniae*     University Hospital                                  ICU and Other Wards                           25              Strain producing both KPC-2 and VIM-1 carbapenemases
  2018       Cairo, Egypt, March 2015 August 2015\[[@B18]\]                              *Serratia marcescens*       University Teaching Hospital                         NICU                                          15              Isolates obtained from blood stream infections

ICU: Intensive care unit; NICU: Neonatal ICU. UK: United Kingdom; USA: United States of America.

###### 

Previous hospital outbreaks of *Serratia marcescens* in Italy

  **Year**   **City**             **Setting**                   **Number of cases** **(Infection and/or colonization)**   **Comments**
  ---------- -------------------- ----------------------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1984       Naples\[[@B22]\]     NICU and Nursery              88                                                        Outbreak linked to contaminated mucus aspiration apparatus and other contaminated instruments. Case fatality rate: 19%
  1988       Genoa\[[@B23]\]      Adult ICU and surgical ward   11                                                        Ventilators for assisted breathing became contaminated from index patient
  1994       Varese\[[@B24]\]     Adult ICU                     43                                                        Strains from the ICU outbreak were multidrug resistance. 23 isolates from 18 other patients from other wards showed wide range of antibiotic susceptibility
  2001       Naples\[[@B25]\]     NICU                          14                                                        56 cases of colonization by S marcescens over a 15-month period. Fourteen of the 56 colonized infants developed clinical infections, 50% of which were major (sepsis, meningitis, or pneumonia)
  2003       Naples\[[@B26]\]     Adult ICU                     13                                                        Strain was multidrug resistant, inducible AmpC betalactamase producing. There were three cases of sepsis, nine pneumonia and one surgical wound infection. Mortality was 84.6%
  2005       Modena\[[@B27]\]     NICU                          15                                                        Simultaneous outbreak of *Serratia marcescens* and Klebsiella pneumonia (11 cases). One preterm baby died in which both organisms were involved
  2007       Pavia\[[@B9]\]       NICU                          21                                                        Occurred in two separate outbreaks in 10 mo interval
  2009       Verona\[[@B28]\]     NICU                          16                                                        6 patients developed clinical diseases which included bacteremia, UTI, conjunctivitis and umbilical wound infection
  2011       Pescara\[[@B7]\]     NICU                          6                                                         5 cases were linked toan index case hospitalised for *S. marcescens* sepsis. Mortality was 40%
  2013       Modena\[[@B6]\]      NICU                          127                                                       Reported two long term outbreaks occurred over a period of 10 years. 43 developed infection and 3 died
  2015       Floerence\[[@B5]\]   NICU                          14                                                        In the surveillance post outbreak, 18 out of 65 patients tested positive for *S. marcescens*

ICU: Intensive care unit; NICU: Neonatal ICU.

CONCLUSION
==========

We report the first European outbreak of VIM-producing *Serratia marcescens* in adult polyvalent ICUs. Two patients developed an infection (bacteremia and LRTI) while one had colonization. No effective therapy is available for the treatment of VIM-producing *S. marcescens*. Methods to detect expression of carbapenem resistance should be widely available in all health care units to prevent the spread of multi-drug organisms and to limit horizontal transfer of the genes associated with drug resistance. Such active surveillance methods will help in averting future outbreaks.

Informed consent statement: Although no personal details are revealed in the present report, informed consent was obtained for publication of this case report along with the related clinical details and images. All clinical data contained in this case report can be made available, in an absolutely anonymized form, upon request to marco.fiore\@unicampania.it.
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